EMA widens public access to drug information
This article was originally published in SRA
The European Medicines Agency has decided that it will, as a general rule, release all business-related documents once a procedure concerning a medicine has been finalised1. The EMA has been heavily criticised in the past for failing to allow public access to information on certain drugs. It says this latest move is intended to give stakeholders a better understanding of its scientific decision-making process.